NK-cells

April 4, 2018

FATE-NK100 Shows Signs of Tumor Reduction in First Ovarian Cancer Patients in Phase 1 Trial

News

FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so ... Read more

March 1, 2017

Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study

News

An investigational drug that boosts the response of natural killer (NK) cells — key players of first-line immune defenses — was recently shown to effectively decrease ovarian tumors in a ... Read more